

## References and Notes

1. National Assessment of Educational Progress, Educational Testing Service, Princeton, NJ 08541, USA.
2. *The National Education Goals Report Executive Summary* (National Educational Goals Panel, Washington, DC, 1995).
3. National Research Council, *National Science Education Standards* (National Academy of Sciences, Washington, DC, 1996).
4. *Curriculum and Evaluation Standards for School Mathematics* (National Council of Teachers of Mathematics, Reston, VA, 1989).
5. *Performance Assessment: Different Needs, Difficult Answers* (Educational Testing Service, Princeton, NJ, 1995); Office of Technology Assessment, U.S. Congress, *Testing in American Schools: Asking the Right Questions?* (Government Printing Office, Washington, DC, 1992); Project 2061, *Benchmarks for Science Literacy* (American Association for the Advancement of Science, Washington, DC, 1993).

\*Former director of NSF's Program in Assessing Student Learning in Science/Mathematics and Senior Scholar in Science Education, Temple University, Philadelphia, PA.

## Antisense Research

As a participant in the *Nature Medicine* conference "The Art of Antisense" (held on 21 and 22 September 1995 in New Orleans, Louisiana), I was disappointed by the Research News article, "Antisense has growing pains" (27 Oct., p. 575) by Trisha Gura. The meeting was intended to be a

forum for discussion of the successes and the challenges in antisense research. Gura emphasized some of the early difficulties and negative results discussed in some of the talks and discussions, yet did not include many of the positive results presented at the conference.

There have been several papers demonstrating specific inhibition of gene expression and corresponding biological activity by oligonucleotides in vitro and in vivo using multiple criteria (1). These publications strongly support the idea that oligonucleotides can, in fact, work by an antisense mechanism of action.

Another focus of the conference was the tremendous advances which have been made in the medicinal chemistry of oligonucleotides. Second and third generation oligonucleotide analogs were described which exhibit greater potency, enhanced nuclease stability, altered pharmacokinetic parameters, and potentially decreased toxicity.

What Gura did emphasize was that the proper use of antisense oligonucleotides is a highly demanding and rigorous scientific challenge, as are most scientific endeavors. This view is in contrast to some of the initial approaches taken, when it was thought that simply designing a single oligonucleotide to hybridize to a target gene,

ordering the oligonucleotide from the DNA synthesis lab, and adding it to cells or animals would result in the selective inhibition of expression of the targeted gene product. Today, we know that carefully controlled studies with multiple oligonucleotides, both control and antisense compounds, are required to demonstrate that they are producing a biological effect as a result of the antisense mechanism of action. Identification of active antisense oligonucleotides requires screening multiple oligonucleotides designed to hybridize to different regions on the target mRNA to identify optimal target sites on the mRNA. Furthermore, it was strongly recommended that the initial screens should directly examine the expression of the targeted gene product, rather than test oligonucleotides by an indirect biological process such as cell proliferation.

It has been demonstrated that oligonucleotides, like any other pharmacological agent, exhibit both expected pharmacological activity and unanticipated activity. To expect otherwise would be naïve. However, because an oligonucleotide produces an unexpected effect, such as polyclonal activation of B lymphocytes or binding to extracellular matrix proteins, it does not mean that all observed biological activities are the result of nonantisense effects of the oligonucleotide. Similarly, it is unlikely that all biological effects of antisense oligonucleotides can be ascribed to an antisense mechanism of action. As with any other pharmacological agent, it is important to perform careful dose response curves as well as structure activity relationships, to correlate in vitro effects with in vivo effects, and to use caution when interpreting data obtained with such agents.

C. Frank Bennett

Vice President, Biology,  
ISIS Pharmaceuticals Inc.,  
2292 Faraday Avenue,  
Carlsbad, CA 92008, USA

## References

1. M. Y. Chiang et al., *J. Biol. Chem.* **266**, 18162 (1991); B. P. Monia et al., *ibid.* **267**, 19954 (1992); A. Colige et al., *Biochemistry* **32**, 7 (1993); B. P. Monia et al., *J. Biol. Chem.* **268**, 14514 (1993); R. W. Wagner et al., *Science* **260**, 1510 (1993); C. F. Bennett et al., *J. Immunol.* **152**, 3530 (1994); N. M. Dean et al., *J. Biol. Chem.* **269**, 16416 (1994); N. M. Dean et al., *Proc. Natl. Acad. Sci. U.S.A.* **91**, 11762 (1994); S. D. Fenster et al., *Biochemistry* **33**, 8391 (1994); L.-W. Zhou et al., *J. Pharmacol. Exp. Ther.* **268**, 1015 (1994); J. L. Duff et al., *J. Biol. Chem.* **270**, 7161 (1995).

### BIOTECH Patent News

**On the Horizon . . .**

Custom Corporation (Emeryville, CA) has applied for a patent covering therapeutic methods utilizing catalytic agents to treat various diseases.

**United States Patents**

**Centocor Infringes XOMA's patent**

XOMA CORPORATION (Berkeley, CA; 415-844-1170) 1990 revenue - \$20 million) won its patent infringement suit against Centocor, Inc. (Malvern, PA; 215-266-4400) 1990 revenue - \$70 million) when a United States District Court jury returned its verdict upholding the validity of XOMA's patent and finding infringement of it by Centocor. The patent covers the use of certain anti-endotoxin monoclonal antibodies in the treatment of humans with gram-negative sepsis.

XOMA has filed suit against Centocor for infringement of United States Patent No. 4,916,163, which was issued to the University of California in April 1990. XOMA is the exclusive licensee of this patent. In addition to upholding the validity of XOMA's patent and XOMA's claim of infringement by Centocor, the jury also denied Centocor's claim of implied license to the patent.

The jury trial, which was presided over by Judge Robert H. Schnacke and conducted in the United States District Court for the Northern District of California in San Francisco, began on July 18.

"We are very gratified by the jury's decision," said Steven C. Mendall, chairman and chief executive officer of XOMA Corporation. "We were confident that once the jury members studied the evidence, they would find in our favor."

XOMA initiated the litigation in April 1990, in order to enforce its rights under the '163 patent. XOMA claimed that Centocor's HA-1A product, an anti-endotoxin antibody, is used in a manner that infringes on the '163 patent. In the next phase of the proceedings, Judge Schnacke will consider whether to enjoin further infringement of the '163 patent.

**WHAT'S THE LATEST NEWS ABOUT PATENTED BIOTECHNOLOGY?**

Understanding the patent news of biotechnology is essential to understanding the business news of biotechnology.

You need to know what biotechnology is being patented. You need to know what biotechnology is being examined by the United States and European Patent Offices. And you need to know how government actions, biotechnology litigations, and research collaborations are affecting patent positions of various companies.

A subscription to **BIOTECH Patent News** can help you make informed decisions about your research and product development strategies.

Let **BIOTECH Patent News** give you an advantage! Twelve monthly issues of important, concise biotechnology patent news cost just \$95.00.

Telephone 908-549-1356 TODAY  
for your FREE issue of

**BIOTECH Patent News**  
or fill out and mail the coupon.  
YOU'LL BE GLAD YOU DID.

## State Key Labs in China

I must compliment *Science* on its effort to let its readers know something about sci-

ence in China through the special section on this topic (17 Nov., pp. 1131–1154). The news article, "Government focuses funds, and hopes, on elite teams," by June Kinoshita (p. 1137) describes the state key, or national, laboratories. As with all national laboratories (1), the State Key Laboratory of Molecular Oncology (SKLMO) depends on the Cancer Institute for administrative support, but it is not under the direction of the Cancer Institute. The director of a state key laboratory is appointed by the responsible ministry, the Ministry of Health for the SKLMO. On the other hand, the Cancer Institute is under the Chinese Academy of Medical Sciences, which in turn is under the Ministry of Health.

Generally, national laboratory directors are selected primarily according to scientific achievement rather than administrative experience. The director of the Cancer Institute has no power to select or appoint someone who is on the same level as or above himself in the administrative hierarchy. China has a strict retirement age limit for administrative positions, consequently, the "academician" (2) mentioned in your article, Wu Min, whom I have the pleasure of knowing, needed no persuasion to step down. The statement

that "It's not easy to convince an academician to step down" is not accurate. Wu was well aware of the age limit and, while still the director of SKLMO, he started looking for a successor and approached Sun Zhong Tan, who was then director, long before Dong Zhiwei was appointed director of the Cancer Institute.

When the state key laboratories were originally initiated, they were commonly called the open laboratories. The original idea was to break up the old stagnancy and encourage personnel exchange among scientific institutions. Each state key laboratory must have a certain proportion of external projects to internal projects. I believe the SKLMO is no exception; even if the director wanted to keep the old stagnancy, the SKLMO wouldn't be able to survive the scrutiny it undergoes by a panel of experts every few years. This system has been instrumental in promoting personnel exchange, much more so than the appointment of a new director to one state key laboratory.

C. L. Tsou

Honorary Director,  
National Laboratory of Biomacromolecules,  
Institute of Biophysics,  
Academia Sinica,  
Beijing, China

## References and Notes

1. For a brief description of state key laboratories in China, see C.-L. Tsou, *FASEB J.* **3**, 2443 (1989).
2. We have members, but not "academicians" in the Chinese Academy of Sciences.

## Corrections and Clarifications

In the News & Comment article "Will NASA's research reforms fly?" (17 Nov., p. 1108), the events surrounding an experiment were incorrectly described on page 1110. The article should have said that a subject wearing an apparatus used to create lower-body negative pressure fainted during a test. (The experiment did not involve injection of a drug.)

## Letters to the Editor

Letters may be submitted by e-mail (at [science\\_letters@aaas.org](mailto:science_letters@aaas.org)), fax (202-289-7562), or regular mail (*Science*, 1333 H Street, NW, Washington, DC 20005, USA). Letters are not routinely acknowledged. Full addresses, signatures, and daytime phone numbers should be included. Letters should be brief (300 words or less) and may be edited for reasons of clarity or space. Letter writers are not consulted before publication.

# THE CHOICE IS SIMPLE

## Dynabeads® for 99% Pure Rapid Cell Separations

*Only Dynabeads primary antibody coated products provide the purity, viability and simplicity required to rapidly isolate phenotypically unaltered cells*

- **Reproducible** Dynabeads uniform shape and size ensures the purity of FACS first time and every time
- **Convenient** Dynabeads are pre-coated with human antibodies to CD2, CD3, CD4, CD8, CD14, CD15, CD19, CD34, CD45 and CD71. All sample sizes can be used without pre-purification steps or costly additional columns.
- **Superior Technology** only Dynabeads coupled with DETACHaBEAD® allow complete detachment of the solid phase resulting in fully functional viable cells. Proven by over 1,000 published references.

Call 1 800 638 9416

 DYNAL®

5 Delaware Drive • Lake Success, NY 11042 • Fax 516 326 3298

Circle No. 36 on Readers' Service Card